Dignitana: Growth not about to cool off - Redeye
Dignitana is a Swedish medical technology company that develops, produces, and markets
the DigniCap: a scalp-cooling system that reduces the hair loss typically associated with
chemotherapy. DigniCap adresses a high unmet medical need – chemotherapy induced hair
loss has an estimated incidence of up to 65% and is ranked as one of the most severe side
effects of chemotherapy treatment among patients.
Using our cautious assumptions on pricing and market share, our 12-year DCF model
indicates a Base Case fair value of SEK 11.5 per share, giving potential upside of some 30%
from current levels.
Länk till uppdragsanalys:
the DigniCap: a scalp-cooling system that reduces the hair loss typically associated with
chemotherapy. DigniCap adresses a high unmet medical need – chemotherapy induced hair
loss has an estimated incidence of up to 65% and is ranked as one of the most severe side
effects of chemotherapy treatment among patients.
Using our cautious assumptions on pricing and market share, our 12-year DCF model
indicates a Base Case fair value of SEK 11.5 per share, giving potential upside of some 30%
from current levels.
Länk till uppdragsanalys:
Commissioned research feed